| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/14/2005 | WO2005032537A1 Method for preventing and/or treating neurodegenerative diseases |
| 04/14/2005 | WO2005032536A1 Drug containing (2r)-2-propyloctanoic acid as the active ingredient |
| 04/14/2005 | WO2005032532A1 Antimycotic composition |
| 04/14/2005 | WO2005032531A1 Antimycotic composition |
| 04/14/2005 | WO2005032530A1 Pharmaceutical composition for external application |
| 04/14/2005 | WO2005032515A1 New use, pharmaceutical preparations as well as a process for their production |
| 04/14/2005 | WO2005032514A1 Transdermal pharmaceutical composition |
| 04/14/2005 | WO2005032513A2 Pantoprazole multiparticulate formulations |
| 04/14/2005 | WO2005032483A2 Polysaccharides for pulmonary delivery of active agents |
| 04/14/2005 | WO2005032470A2 Compositions and methods for treating burns |
| 04/14/2005 | WO2005032401A2 Pressure-sensitive adhesive sheet for application to skin |
| 04/14/2005 | WO2005014050A3 Conjugates of hydroxyalkyl starch and g-csf |
| 04/14/2005 | WO2005011738A3 Polymeric conjugates containing phosphine - based chelating groups |
| 04/14/2005 | WO2005011641A3 Improved stearate composition and method of production thereof |
| 04/14/2005 | WO2004096989A3 Single chain antigen-binding polypeptides for polymer conjugation |
| 04/14/2005 | WO2004070019A3 Membrane active polymers |
| 04/14/2005 | WO2003051287A3 Topical compositions and methods for treatment of adverse effects of ionizing radiation |
| 04/14/2005 | WO2002079417A3 Methods of delivery of exogenous proteins to the cytosol and uses thereof |
| 04/14/2005 | US20050080265 Sleep disorders; side effect reduction |
| 04/14/2005 | US20050080206 Reacting polyethylene glycol with difunctional activator in presence of a tert-aminopyridine base, preferably at room temperature, and under stoichiometric conditions; activators include alkylenebis(sulfuryl halides), alkylenebis(haloformates) and nitrophenoxyalkylene-sulfuryl halides and -haloformates |
| 04/14/2005 | US20050080137 Laxative preparation |
| 04/14/2005 | US20050080064 Steroids as agonists for fxr |
| 04/14/2005 | US20050080051 for the treatment of hyperlipidemia and blood coagulation disorders; phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, or phosphatidic acid; dyslipidemia and atherosclerosis |
| 04/14/2005 | US20050080046 In liquid solvent; parenterally administering; aldosterone receptors blockers; congestive heart failure, hypotensive agents, liver disorders |
| 04/14/2005 | US20050080045 topical administration; prevention of STDs preferably a viral disease other than HIV, e.g. HPV or genital herpes and especially acyclovir resistant genital herpes |
| 04/14/2005 | US20050080043 stable without buffer and maintain a stable pH at pH 3.5 or lower |
| 04/14/2005 | US20050080033 Biodegradable polyacetals for in vivo polynucleotide delivery |
| 04/14/2005 | US20050080031 Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV |
| 04/14/2005 | US20050080029 Administering to the cell the compound to be delivered, an organic halide, and/or a carrier; ultrasound may also be applied |
| 04/14/2005 | US20050080028 Ballast administering to mammals skins; high density core overcoated with amorphous reservoir containing dna; drug delivery; containing free radical scavenger |
| 04/14/2005 | US20050080012 Comprising controlled substance and amino acid or polypeptide covalently bound to controlled substance in manner that renders controlled substance pharmacologically inactive; when delivered by oral route controlled substance is released in time-dependent manner by acid hydrolysis and/or enzyme cleavage |
| 04/14/2005 | US20050080009 Storage-stable, liquid fibrinogen formulation |
| 04/14/2005 | US20050080006 Apo2L/TRAIL formulations including lyophilized and crystal compositions; may be used in inducing apoptosis in mammalian cells including cancer cells by exposing mammalian cells to an effective amount of an Apo-2 ligand formulation described herein |
| 04/14/2005 | US20050080001 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| 04/14/2005 | US20050079610 Using short interfering RNA's specific to oncogene (fos) as tool in prevention and treatment of infection, allergies, cell proliferatiove, inflammatory and autoimmune diseases |
| 04/14/2005 | US20050079593 Modified enzymes having polymer conjugates |
| 04/14/2005 | US20050079541 Immunoadhesin comprising a glycorprotein v1 domain |
| 04/14/2005 | US20050079260 Methods for reducing astringency |
| 04/14/2005 | US20050079253 Bilayer edible sheet |
| 04/14/2005 | US20050079245 Addition of a liquid coating syrup to a moving mass of cores for comestibles in a rotating pan and obtaining a plurality of sugar-free hard-coated comestibles having a hard coating on an edible, chewable and/or pharmaceutical core wherein layer of hard coating is directly in contact with core |
| 04/14/2005 | US20050079225 Methods and therapeutic compositions in the treatment of advanced cancer |
| 04/14/2005 | US20050079224 Residual solvent extraction method and microparticles produced thereby |
| 04/14/2005 | US20050079222 Using crosslinked particles of maleic(acid or anhydride)-methyl vinyl ether copolymer |
| 04/14/2005 | US20050079218 Matrices for the stabilizing and controlled release of problematic substances |
| 04/14/2005 | US20050079217 Tablet with protective coatings; Parkinson's disease; sexual disorders |
| 04/14/2005 | US20050079216 Tablets, pellets in active matrix copolymer; melting, injection molding, extrusion, granulation |
| 04/14/2005 | US20050079210 Mixing, heating with liposome forming material with cosmetics, drugs and solubilizer; cooling |
| 04/14/2005 | US20050079209 Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 04/14/2005 | US20050079208 Methods of modulating antigen-specific T cell activity |
| 04/14/2005 | US20050079194 Cosmetic compositions comprising alk(en)ylsuccinic acid derivatives |
| 04/14/2005 | US20050079179 Compositions and methods for producing vascular occlusion |
| 04/14/2005 | US20050079166 Drug delivery; heating substrate ; solid fuels; exothermic metal oxidation ; high speed vaporization of drug |
| 04/14/2005 | US20050079155 Generating protein pro-drugs using reversible PPG linkages |
| 04/14/2005 | US20050079148 Biocompatible polymer designed to release nitric oxide; extensively cross-linked polyamine-derivatized divinylbenzene; sustained release, potentiation |
| 04/14/2005 | US20050079145 Stabilized reverse micelle compositions and uses thereof |
| 04/14/2005 | US20050079137 Heat resistant active material ; mixture with propylene glycol and an excipients |
| 04/14/2005 | US20050079136 Therapy for pain, appetite inttensifiers, multiple sclerosis and asthma; drug delivery |
| 04/14/2005 | CA2541243A1 Pressure-sensitive adhesive sheet for application to skin |
| 04/14/2005 | CA2540742A1 Compositions and methods for treating burns |
| 04/14/2005 | CA2540699A1 Polysaccharides for pulmonary delivery of active agents |
| 04/14/2005 | CA2540671A1 Infusion preparation containing (2r)-2-propyloctanoic acid as the active ingredient |
| 04/14/2005 | CA2540670A1 Drug containing (2r)-2-propyloctanoic acid as the active ingredient |
| 04/14/2005 | CA2540666A1 Glucocerebroside treatment of disease |
| 04/14/2005 | CA2540537A1 New use, pharmaceutical preparations as well as a process for their production |
| 04/14/2005 | CA2540467A1 Compositions and methods for augmenting kidney function |
| 04/14/2005 | CA2540357A1 Telechelic homopolyamino acids functionalized by hydrophobic groups and uses, particularly therapeutic, thereof |
| 04/14/2005 | CA2539982A1 Pantoprazole multiparticulate formulations |
| 04/14/2005 | CA2539023A1 Triamcinolone acetonide and anecortave acetate formulations for injection |
| 04/14/2005 | CA2524209A1 Antiviral agents for the treatment, control and prevention of infections by coronaviruses |
| 04/13/2005 | EP1522583A2 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sina) |
| 04/13/2005 | EP1522539A1 Crystalline composition containing escitalopram |
| 04/13/2005 | EP1522318A2 Heat stable coated colloidal iron oxides |
| 04/13/2005 | EP1522317A1 Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles |
| 04/13/2005 | EP1522316A1 Transdermal absorption preparation |
| 04/13/2005 | EP1522312A1 Biologically stable liquid composition of FVIII, of vWF or of FVIII/vWF complex of human origin. |
| 04/13/2005 | EP1522225A1 Bilayer edible sheet |
| 04/13/2005 | EP1522219A1 Antiparasitic formulations |
| 04/13/2005 | EP1521795A2 Heat-sensitive polymers and heat reversible gels derived therefrom |
| 04/13/2005 | EP1521779A1 Compounds that bind to the interferon-gamma, preparation method thereof and medicaments containing same |
| 04/13/2005 | EP1521769A2 Tubulysin conjugates |
| 04/13/2005 | EP1521768A2 RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 04/13/2005 | EP1521600A2 Bisacyloxypropylcysteine conjugates and the use thereof |
| 04/13/2005 | EP1521599A2 Absorption enhancing agent |
| 04/13/2005 | EP1521597A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 04/13/2005 | EP1521596A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 04/13/2005 | EP1521595A1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 04/13/2005 | EP1521593A2 Transdermal botulinum toxin compositions |
| 04/13/2005 | EP1521589A2 Bioactivation of particles |
| 04/13/2005 | EP1521580A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists |
| 04/13/2005 | EP1521576A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and pde-iv inhibitors |
| 04/13/2005 | EP1521575A1 Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds |
| 04/13/2005 | EP1521574A1 Solid pharmaceutical composition containing a lipophilic active principle and preparation method thereof |
| 04/13/2005 | EP1521573A1 Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
| 04/13/2005 | EP1521572A1 Bioerodible film for ophthalmic drug delivery |
| 04/13/2005 | EP1521571A1 Solid dispersion comprising two different polymer matrixes |
| 04/13/2005 | EP1521570A1 Oral dosage form comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition |
| 04/13/2005 | EP1521535A1 Improved bulking agent composition |
| 04/13/2005 | EP1480736A4 Microcapsules having high carotenoid content |
| 04/13/2005 | EP1476193A4 A weight management system for obese animals |
| 04/13/2005 | EP1474171A4 Weight management system for obese animals |